This post was originally published on this site Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s lymphoma. This approval — which makes the regimen accessible to physicians and eligible patients in Canada — was…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
$4.6M CIRM Grant to Fund Phase 1 Trial of New Immunotherapy for Advanced Sarcoma, Difficult-to-Treat Cancers
This post was originally published on this site The California Institute for Regenerative Medicine (CIRM) has awarded a $4.6 million grant to researchers at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research for an ongoing Phase 1 clinical trial testing a new immunotherapy for advanced sarcoma and other hard-to-treat cancers.…
Here I Am
This post was originally published on this site I remember when my daughter performed at a talent show at her school. I’d just had my fourth round of chemotherapy, and my condition was critical. For me, every chemo session had its own little life cycle, each with a unique set of challenges and logistics. Because…
Evidence Supports Stereotactic Body Radiotherapy as a Standard of Care for Localized PC
This post was originally published on this site Cumulative evidence to date supports the implementation of stereotactic body radiotherapy — a highly precise radiation therapy delivered in shorter periods of time — as a standard treatment for people with localized prostate cancer, a study shows. The study, “Stereotactic Body Radiotherapy for Localized Prostate Cancer: A…
ctDNA Sampling May Help Tailor Treatment for Difficult-to-Treat Ovarian Cancer, Study Suggests
This post was originally published on this site An analysis of circulating tumor DNA, or ctDNA, can help guide treatment decisions for patients with difficult-to-treat high-grade serous ovarian cancer, a study shows. The study, “Prospective Longitudinal ctDNA Workflow Reveals Clinically Actionable Alterations in Ovarian Cancer,” was published in journal Precision Oncology. Cancers generally develop due…
Phase 3 Trial of Immune System-targeting Treatment for Advanced Multiple Myeloma Begins Dosing
This post was originally published on this site A pivotal Phase 3 clinical trial has begun dosing participants to evaluate MorphoSys‘s investigational antibody, MOR202 (TJ202), in combination with Revlimid (lenalidomide) plus dexamethasone, for the treatment of relapsed or refractory multiple myeloma. The study, ongoing in Taiwan, is being conducted by I-Mab Biopharma, which holds exclusive…
Radiation Therapy Reduces Chances of Breast Cancer Returning in Women with Early, Hormone-Positive Disease, Trial Shows
This post was originally published on this site Women with early, low-risk hormone receptor-positive breast cancer are significantly less likely to see their disease return if given radiation therapy and hormone therapy following surgery, according to a trial that followed hundreds of women for nearly 10 years. Specifically, the trial found that whole breast irradiation…
Dutch Researchers Develop Mini Ovarian Cancers to Improve Personalized Therapies
This post was originally published on this site Dutch researchers have developed a new experimental protocol that allowed them to culture mini ovarian cancers (organoids) in the lab that retained their three-dimensional structure and captured the cellular diversity seen in patients. These organoids, which mimic the cellular environment and treatment responses in patients, may be…
OncLive Poised to Induct 2019 Class of ‘Giants of Cancer Care’
This post was originally published on this site OncLive, a digital resource platform for oncologists, will welcome 15 new members at its 7th Annual Giants of Cancer Care Winners Reception on May 30 in Chicago, Illinois. Inductees are being recognized for furthering the field of oncology, including multiple myeloma, through research and clinical practices. “We are looking…
Famous Lymphoma Survivors Can Be Models for Hope
This post was originally published on this site I don’t like to think about death, much less write about it. Over 11 years as a follicular lymphoma patient, I’ve gotten pretty good at not thinking about it. But now and then, something happens that makes it unavoidable. Like when a famous person with lymphoma, such…
Kadcyla Approved in US for Some HER2-positive Early Breast Cancer Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has extended the use of Genentech‘s Kadcyla (ado-trastuzumab emtansine) as an adjuvant (post-surgery) treatment for some patients with HER2-positive, early-stage breast cancer, the company announced. Specifically, the FDA’s approval is for patients who had residual disease after their pre-surgery treatment, which included a…
Single Dose of Brachytherapy Safe, Effective for Localized PC, Study Shows
This post was originally published on this site Men with low-risk prostate cancer can safely receive a single high dose of brachytherapy — a type of radiation therapy delivered directly into the tumor within a few minutes — as an alternative treatment for their condition, a study shows. After three years of treatment, 100% of…